Key result
Total plasma homocysteine is established as a clinical risk factor for coronary artery disease and other arterial and venous occlusive diseases.
Why the study?
Does folate and B vitamin supplementation reduce the risk of vaso-occlusive disease in patients with hyperhomocysteinemia?
Does folate and B vitamin supplementation reduce the risk of vaso-occlusive disease in patients with hyperhomocysteinemia?
Total plasma homocysteine is a clinical risk factor for coronary artery disease, suggesting that treatment of hyperhomocysteinemia with folate and B vitamins may reduce disease risk.
No takes yet. Share an insight, caveat, or question.
Homocysteine established as CAD risk factor; leaves open whether folate/B-vitamin supplementation reduces vaso-occlusive events.
Langman et al. (1999) conducted a review in Coronary artery disease and vaso-occlusive disease. Total plasma homocysteine was evaluated. Total plasma homocysteine is established as a clinical risk factor for coronary artery disease and other arterial and venous occlusive diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: